Subcutaneous versus intramuscular depot methoxyprogesterone acetate: A comparative review

Melissa A. Simon, Lee P. Shulman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Depot medroxyprogesterone acetate (DMPA; Depo-Provera) is a highly effective and convenient contraceptive method that has been used worldwide for many decades. Recently, a new lower dose of DMPA, administered as a subcutaneous injection, has been approved for use in the USA as a contraceptive and a treatment for pain associated with endometriosis. The newer formulation has a similar efficacy to the older version and, more importantly, has fewer side effects, with improved user tolerability. Similar to the intramuscular DMPA injection (Depo-Provera intramuscular or contraceptive injection), the subcutaneous injection provides effective contraceptive and pain-management therapy for endometriosis, with a 3-monthly injectable protocol for women who seek long-term and reversible contraception without the need for a daily pill or a more frequent dosing regimen.

Original languageEnglish (US)
Pages (from-to)191-197
Number of pages7
JournalWomen's Health
Issue number2
StatePublished - Mar 2006


  • Contraception
  • Family planning
  • Subcutaneous injection
  • Subcutaneous medroxyprogesterone acetate
  • Women's health

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Subcutaneous versus intramuscular depot methoxyprogesterone acetate: A comparative review'. Together they form a unique fingerprint.

Cite this